Loading viewer...
investor_presentation
Format: PDF investor_presentation
Zilucoplan, a Subcutaneously Self -Administered Peptide Inhibitor of Complement Component 5 (C5), for the Treatment of Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double -Blind, Placebo -Controlled Trial and Open -Label Long -Term Extension James F. Howard, Jr
presentation
investor_presentation
Biogen
investor_presentation
2U-Inc
investor_presentation
ChemX Materials